115 related articles for article (PubMed ID: 15118480)
1. Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers.
Calvo G; García-Gea C; Luque A; Morte A; Dal-Ré R; Barbanoj M
J Clin Psychopharmacol; 2004 Jun; 24(3):268-76. PubMed ID: 15118480
[TBL] [Abstract][Full Text] [Related]
2. Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers.
Barbanoj MJ; Clos S; Romero S; Morte A; Giménez S; Lorenzo JL; Luque A; Dal-Ré R
Neuropsychobiology; 2005; 51(3):134-47. PubMed ID: 15838185
[TBL] [Abstract][Full Text] [Related]
3. Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.
Kroboth PD; Folan MM; Lush RM; Chaikin PC; Shukla UA; Barbhaiya R; Salazar DE
J Clin Psychopharmacol; 1995 Oct; 15(5):306-19. PubMed ID: 8830061
[TBL] [Abstract][Full Text] [Related]
4. Dose-response evaluation of the interaction between sertraline and alprazolam in vivo.
Hassan PC; Sproule BA; Naranjo CA; Herrmann N
J Clin Psychopharmacol; 2000 Apr; 20(2):150-8. PubMed ID: 10770452
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.
Lasher TA; Fleishaker JC; Steenwyk RC; Antal EJ
Psychopharmacology (Berl); 1991; 104(3):323-7. PubMed ID: 1924640
[TBL] [Abstract][Full Text] [Related]
6. Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers.
Barbanoj MJ; Urbano G; Antonijoan R; Ballester MR; Valle M
Neuropsychobiology; 2007; 55(3-4):203-12. PubMed ID: 17878744
[TBL] [Abstract][Full Text] [Related]
7. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam.
Yasui N; Kondo T; Otani K; Furukori H; Kaneko S; Ohkubo T; Nagasaki T; Sugawara K
Psychopharmacology (Berl); 1998 Oct; 139(3):269-73. PubMed ID: 9784084
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship.
Wright CE; Sisson TL; Fleishaker JC; Antal EJ
J Clin Pharmacol; 1997 Apr; 37(4):321-9. PubMed ID: 9115058
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans.
Busto U; Kaplan HL; Zawertailo L; Sellers EM
Clin Pharmacol Ther; 1994 Apr; 55(4):451-63. PubMed ID: 8162672
[TBL] [Abstract][Full Text] [Related]
10. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine.
Goldberg MR; Lowry RC; Musson DG; Birk KL; Fisher A; De Puy ME; Shadle CR
J Clin Pharmacol; 1999 Feb; 39(2):192-9. PubMed ID: 11563413
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers.
Hindmarch I; Trick L; Ridout F
Psychopharmacology (Berl); 2005 Dec; 183(2):133-43. PubMed ID: 16205916
[TBL] [Abstract][Full Text] [Related]
12. Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users.
Schoedel KA; Stockis A; Sellers EM
Epilepsy Behav; 2018 Jan; 78():194-201. PubMed ID: 29153631
[TBL] [Abstract][Full Text] [Related]
13. A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam.
Busto UE; Kaplan HL; Wright CE; Gomez-Mancilla B; Zawertailo L; Greenblatt DJ; Sellers EM
J Clin Psychopharmacol; 2000 Dec; 20(6):628-35. PubMed ID: 11106134
[TBL] [Abstract][Full Text] [Related]
14. Do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course?
Kroboth PD; Folan MM; Bauer KS; Tullock W; Wright CE; Sweeney JA
J Clin Pharmacol; 1998 Apr; 38(4):337-46. PubMed ID: 9590461
[TBL] [Abstract][Full Text] [Related]
15. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism.
Yasui N; Otani K; Kaneko S; Ohkubo T; Osanai T; Sugawara K; Chiba K; Ishizaki T
Clin Pharmacol Ther; 1996 May; 59(5):514-9. PubMed ID: 8646822
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.
Fleishaker JC; Hulst LK
Eur J Clin Pharmacol; 1994; 46(1):35-9. PubMed ID: 8005185
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users.
Schoedel KA; Andreas JO; Doty P; Eckhardt K; Sellers EM
J Clin Psychopharmacol; 2017 Dec; 37(6):675-683. PubMed ID: 28926353
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state.
Scavone JM; Greenblatt DJ; Goddard JE; Friedman H; Harmatz JS; Shader RI
Eur J Clin Pharmacol; 1992; 42(4):439-43. PubMed ID: 1516609
[TBL] [Abstract][Full Text] [Related]
19. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam.
Kaplan GB; Greenblatt DJ; Ehrenberg BL; Goddard JE; Harmatz JS; Shader RI
J Clin Psychopharmacol; 2000 Jun; 20(3):338-46. PubMed ID: 10831021
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
Chen L; Boinpally R; Gad N; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
Clin Drug Investig; 2015 Oct; 35(10):601-12. PubMed ID: 26315684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
